Post by cretin11 on Sept 6, 2018 11:25:39 GMT -5
$2.27M each is due AMPH on 9/21/18, 12/21/18. Mnkd needs the insulin to supply Brazil market besides the U.S.
SO said:
There will be a filing relating to the initiation of a phase 3 trial on Tre-T in the not too distant future, as well as possible applications for Mexico and Canada. These three binary events could provide equity appreciation leeway to see 14 million warrants exercised at $2.38 in the Fall. If that happens, the MannKind cash runway would extend to the end of Q1 of 2019.
we can likely see a small milestone payment on Tre-T in Q1 with the initiation of the phase 3 clinical trial, and a bigger payment a year later with FDA approval followed by a third in mid 2020 related to the launch.
Previous deals like the one with RLS were with upstart companies trying to find an identity. United Therapeutics is a sizable company that controls much of the PAH market. This new cachet can assist MannKind in trying to solve its finances by providing the company with better leverage in negotiating recapitalization, partnerships, and even future offerings. The emergence of a second product also allows the company to work toward development of other new products which could give a big boost to the viability of the company, and the equity it represents. Simply stated, this is a positive for MannKind, and while it is not the ultimate solution, it is a big step in a good direction.
I’d like to add a new global international Afrezza deal might be possible Covering the world but Brazil, India, Mexico, Canada, U.S. per MC discussion. This deal should have good upfront money.
